Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 3 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Synovial 1 Sarcoma 1 Recurrence 1 Neurofibrosarcoma 1 Lymphoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Gliosarcoma 1 Glioblastoma 1 Dermatofibrosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Advanced Nonhematological Neoplasms 1

Interventions

Rituximab 66 Cyclophosphamide 52 fludarabine phosphate 26 fludarabine 22 Filgrastim 21 Vincristine 19 Methotrexate 19 Melphalan 19 Doxorubicin 18 Radiotherapy 17 Etoposide 17 Prednisone 16 Tacrolimus 15 Whole-Body Irradiation 14 Mycophenolic Acid 14 Cytarabine 14 Peripheral Blood Stem Cell Transplantation 13 Gemcitabine 13 Cyclosporine 13 Antilymphocyte Serum 13 Lenalidomide 12 Busulfan 11 Bortezomib 11 Granulocyte Colony-Stimulating Factor 9 Alemtuzumab 9 sargramostim 8 Dexamethasone 8 Cord Blood Stem Cell Transplantation 8 pembrolizumab 7 ibritumomab tiuxetan 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Lymphoma × sapanisertib × Clear all

NCT02727777 2020-03-12

Phase II Study of TAK228 in Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated

4 enrolled 9 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡